| hyp-SDA-2026-04-09-g | Glycosyltransferase Modulation for Tau Vesicle Marking | 0.46 | 0.50 | MGAT5 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan-Targeting Tau Vesicle Interceptors | 0.46 | 0.50 | ST6GAL1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan-Based Drug Delivery to Tau Vesicles | 0.46 | 0.50 | ST6GAL1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Lectin-Mediated Autophagy Enhancers | 0.46 | 0.50 | LGALS3 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan Pattern Disruption via Metabolic Intervention | 0.46 | 0.50 | HK1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Vesicle Size-Selective Nanobody Penetration | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | ATP Depletion-Responsive Penetrating Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Membrane Curvature-Responsive Cell-Penetrating Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Cholesterol Depletion-Targeting Nanobody Vectors | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Phosphatidylserine-Targeting Nanobody Chimeras | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | pH-Activated Membrane Fusion Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Tau Conformational Change-Triggered Membrane Disruption | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Temporal Gating Through HSP70 ATPase Cycle Manipulation | 0.46 | 0.50 | HSPA1A | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Phosphorylation-State Dependent Inhibition | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Tau Conformation-Selective HSP70 Inhibition | 0.46 | 0.50 | HSPA1A | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Membrane-Localized HSP90 Disruption | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Co-chaperone Hijacking Strategy | 0.46 | 0.50 | HSPA1A | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Competitive Co-chaperone Displacement | 0.46 | 0.50 | FKBP5 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Combinatorial PTM signatures distinguish pathological from physiological tau sta | 0.46 | 0.50 | MAPT | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-09-g | p300/CBP-dependent K280 acetylation nucleates pathogenic tau conformers | 0.46 | 0.50 | EP300 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-09-g | Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seed | 0.46 | 0.50 | CASP2/CASP3 | active | 2026-04-27 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-08-g | Magnetic Field Stimulation for Memory Consolidation | 0.46 | 0.50 | Cryptochromes (CRY1, CRY2), magnetoreceptor proteins | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Developmental Critical Period Extension for Memory Recovery | 0.46 | 0.50 | PSD-95, CREB, perineuronal net components | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Epigenetic Memory Engram Therapy for Alzheimer's Disease | 0.46 | 0.50 | DNMT3A, CREB-binding protein (CBP) | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Social Memory Network Enhancement Therapy | 0.46 | 0.50 | Oxytocin receptor (OXTR), mirror neuron networks | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Circadian-Spatial Memory Coupling for Navigation Disorders | 0.46 | 0.50 | CLOCK, BMAL1, hippocampal place cells | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Stress-Resilient Memory Formation Protocol | 0.46 | 0.50 | FKBP5, glucocorticoid receptor (GR), BDNF | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Metabolic Memory Support Therapy | 0.46 | 0.50 | AMPK, PGC-1α, mitochondrial complex proteins | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Magnetic Field Sensing-Memory Interface Therapy | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Epigenetic ADCY8 Memory Programming | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Circadian-Spatial Memory Coupling Therapy | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | ADCY8-Mediated Synaptic Tagging for Spatial Memories | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Hippocampal ADCY8 Upregulation for Alzheimer's Navigation Deficits | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | ADCY8-cAMP Memory Consolidation Enhancer | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | ADCY8-PKA-CREB Spatial Memory Enhancement | 0.46 | 0.50 | ADCY8 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Ribosomal Stress Response Exploitation | 0.46 | 0.50 | LTN1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Cytoskeletal Transport Selectivity Enhancement | 0.46 | 0.50 | KIF5A | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Membrane Lipid Composition Therapeutic Modulation | 0.46 | 0.50 | HMGCR | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Phase Separation Modulation Therapy | 0.46 | 0.50 | FUS | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Chaperone Network Reprogramming Therapy | 0.46 | 0.50 | HSPA1A | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Mitochondrial Proteostasis Coupling Therapy | 0.46 | 0.50 | ATF5 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Lysosomal pH Gradient Manipulation | 0.46 | 0.50 | ATP6V1A | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Dual SPI1 Inhibition for Atherosclerosis-Neurodegeneration Axis | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Epigenetic SPI1 Reprogramming Therapy | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | SPI1-C1Q Transcriptional Circuit Drives Cerebrovascular Neuroinflammation | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Neurovascular Unit SPI1 Signaling Hub | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Microglial SPI1 Priming by Circulating C1Q | 0.46 | 0.50 | C1Q | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Temporal SPI1 Inhibition for Neuroplasticity Recovery | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | SPI1-Mediated Metabolic Reprogramming in Neuroinflammation | 0.46 | 0.50 | SPI1 | active | 2026-04-27 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |